A third set of authoritative results from UK trial ruled out use of AbbVie's HIV combination, plus Bharat Biotech to launch Phase I vaccine trials.
A large randomized trial of AbbVie Inc.’s Kaletra (lopinavir-ritonavir) has been found to have no benefits for patients hospitalized with COVID-19, despite early hopes for the HIV combination therapy.
The result are the third major finding of the adaptive RECOVERY trial led by the University of Oxford in the UK, which set up in March a large-scale randomized study of
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
